PT - JOURNAL ARTICLE AU - Caitlin T Fierheller AU - Laure Guitton-Sert AU - Wejdan M Alenezi AU - Timothée Revil AU - Kathleen K Oros AU - Karine Bedard AU - Suzanna L Arcand AU - Corinne Serruya AU - Supriya Behl AU - Liliane Meunier AU - Hubert Fleury AU - Eleanor Fewings AU - Deepak N Subramanian AU - Javad Nadaf AU - Diane Provencher AU - William D Foulkes AU - Zaki El Haffaf AU - Anne-Marie Mes-Masson AU - Jacek Majewski AU - Marc Tischkowitz AU - Paul A James AU - Ian G Campbell AU - Celia M T Greenwood AU - Jiannis Ragoussis AU - Jean-Yves Masson AU - Patricia N Tonin TI - The genetic analysis of a founder Northern American population of European descent identifies <em>FANCI</em> as a candidate familial ovarian cancer risk gene AID - 10.1101/2020.05.04.20090407 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.04.20090407 4099 - http://medrxiv.org/content/early/2020/05/08/2020.05.04.20090407.short 4100 - http://medrxiv.org/content/early/2020/05/08/2020.05.04.20090407.full AB - Some familial ovarian cancer (OC) could be due to rare risk alleles in genes that each account for a relatively small proportion of cases not due to BRCA1 and BRCA2, major risk genes in the homologous recombination (HR) DNA repair pathway. We report a new candidate OC risk allele, FANCI c.1813C&gt;T in a Fanconi anemia (FA) gene that plays a role upstream of the HR DNA repair pathway. This variant was identified by whole exome sequencing of a BRCA1 and BRCA2 mutation-negative French Canadian (FC) OC family from a population exhibiting founder effects. In FCs, the c.1813C&gt;T allele was detected in 7% (3/43) of familial and 1.6% (7/439) of sporadic OC cases; and in 3.7% (3/82) of familial breast cancer (BC) cases with a family history of OC and in 1.9% (3/158) of BC only families. This allele was significantly associated with FC BRCA1 and BRCA2 mutation-negative OC families (OR=5.6; 95%CI=1.6-19; p=0.006). Although FANCI c.1813C&gt;T was detected in 2.5% (74/2950) of cancer-free FC females, carriers had a personal history of known OC risk reducing factors, and female/male carriers were more likely to have reported a first-degree relative with OC (ρ=0.037; p=0.011). Eight rare potentially pathogenic FANCI variants were identified in 3.3% (17/516) of Australian OC cases, including 10 carriers of FANCI c.1813C&gt;T. Potentially pathogenic FANCI variants were significantly more common in AUS OC cases with a family history of OC than in isolated OC cases (p=0.027). The odds ratios (OR) were &gt;3 for carriers of any of the seven rarest FANCI alleles, and 1.5 for c.1813C&gt;T. Data from the OC Association Consortium revealed that the ORs for the c.1813C&gt;T allele were highest for the most common OC subtypes. Localization of FANCD2, part of the FANCI-FANCD2 (ID2) binding complex in the FA pathway, to sites of induced DNA damage was severely impeded in cells expressing the p.L605F isoform. This isoform was expressed at a reduced level; unstable by formaldehyde or mitomycin C treatment; and exhibited sensitivity to cisplatin but not to olaparib (a poly [ADP-ribose] polymerase inhibitor). By tissue microarray analyses, FANCI protein was robustly expressed in fallopian tube epithelial cells but expressed at low-to-moderate levels in 88% (83/94) of high-grade serous carcinoma OC samples. This is the first study to describe potentially pathogenic variants in OC in a member of the ID2 complex of the FA DNA repair pathway. Our data suggest that potentially pathogenic FANCI variants may modify OC risk in cancer families.Competing Interest StatementThe authors have declared no competing interest.Funding StatementC.T.F. was supported by The Research Institute of the McGill University Health Centre Studentship (RI-MUHC) Award and Ovarian Cancer Canada Trainee Travel (Research) Award. W.M.A. is supported by a Taibah University Scholarship Award and The Ministry of Higher Education, Saudi Arabia. H.F. was supported in part by the Michèle St-Pierre and Canderel fellowships of the Institut du cancer de Montréal. L.G.-S. is supported by a Fonds de recherche du Québec-Santé (FRQS) Fellowship Award and J.-Y.M. is a FRQS Research Chair in Genome Stability. The RI-MUHC and CRCHUM receive support from the FRQS. Research was supported by the following: The Canadian Institute for Health Research (CIHR) operating grants [PCC-156736 to P.N.T., C.M.T.G., J.R.; PJT-156124 to P.N.T., J.R.]; Cancer Research Society and Ovarian Cancer Canada partnership grant [21123 to P.N.T.; Department of Medicine, McGill University Grant to P.N.T.; FRQS and Quebec Breast Cancer Foundation network grants to P.N.T.; Compute Canada resource allocation project wst-164 and Genome Canada Genome Technology Platform award to J.R.; CIHR foundation grant to J.-Y.M. Ovarian tumor banking was supported by the Banque de tissus et de données of the Réseau de recherche sur le cancer of the FRQS affiliated with the Canadian Tumor Repository Network (CTRNet). Funding for BCAC and iCOGS came from: Cancer Research UK [grant numbers C1287/A16563, C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565], the European Union’s Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), the European Community’s Seventh Framework Programme under grant agreement n° 223175 [HEALTHF2-2009-223175] (COGS), the National Institutes of Health [CA128978] and Post-Cancer GWAS initiative [1U19 CA148537, 1U19 CA148065-01 (DRIVE) and 1U19 CA148112 - the GAME-ON initiative], the Department of Defence [W81XWH-10-1-0341], and the Canadian Institutes of Health Research CIHR) for the CIHR Team in Familial Risks of Breast Cancer [grant PSR-SIIRI-701]. All studies and funders as listed in Michailidou K et al (2013 and 2015) and in Guo Q et al (2015) are acknowledged for their contributions.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUnknown